Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News First Wave BioPharma Inc FWBI

Healthcare Biotechnology
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted... see more

Recent & Breaking News (NDAQ:FWBI)

AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma

GlobeNewswire September 14, 2021

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

GlobeNewswire September 13, 2021

AzurRx BioPharma Announces Reverse Stock Split

GlobeNewswire September 10, 2021

AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire September 10, 2021

AzurRx BioPharma Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire September 9, 2021

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

GlobeNewswire September 8, 2021

AzurRx BioPharma to Present at the Virtual H.C. Wainwright 23rd Annual Global Investment Conference

GlobeNewswire September 7, 2021

AzurRx BioPharma Announces Positive Topline Data For Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency (EPI)

GlobeNewswire August 18, 2021

AzurRx BioPharma Announces WHO Publication of "Adrulipase Alfa" as International Nonproprietary Name for MS1819

GlobeNewswire August 17, 2021

AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors

GlobeNewswire August 16, 2021

AzurRx BioPharma Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire August 12, 2021

AzurRx BioPharma Adds New Clinical Trial Sites in Ukraine for Phase 2 RESERVOIR Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire August 10, 2021

AzurRx BioPharma Announces Closing of $5.75 Million Bought Deal Offering and Exercise in Full of Underwriter's Option to Purchase Additional Shares

GlobeNewswire July 27, 2021

AzurRx BioPharma Increases Previously Announced Bought Deal to $5.0 Million

GlobeNewswire July 22, 2021

AzurRx BioPharma Announces $3.0 Million Bought Deal Offering of Common Stock

GlobeNewswire July 22, 2021

AzurRx BioPharma CEO James Sapirstein to Present at 2021 BIO Digital

GlobeNewswire June 8, 2021

AzurRx BioPharma Doses First Patient In Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

GlobeNewswire June 7, 2021

UPDATE - FMW Media, Inc.'s "New to The Street" TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET

GlobeNewswire June 4, 2021

FMW Media, Inc.'s "New to The Street" TV Announces 6 Interviews Being Broadcast on NEWSMAX TV, Sunday, June 06, 2021, Hour Slot 10-11 AM ET

GlobeNewswire June 4, 2021

AzurRx BioPharma to Present at Rocky Mountain Microcap Conference (May 26)

GlobeNewswire May 19, 2021